Press Releases

Print Page Print Page        E-mail Page Email Page        RSS Feeds RSS        E-mail Alerts Email Alerts        Financial Tear Sheet Tear Sheet
Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
12/08/10Alkermes Announces Results from Phase 2 Study of ALKS 33 in Alcohol DependencePrinter Friendly Version
11/16/10Alkermes Presents Promising Preclinical Data on ALKS 33 for Multiple Disease Indications at Annual Meeting of the Society for NeurosciencePrinter Friendly Version
11/10/10Alkermes' Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare ConferencePrinter Friendly Version
11/05/10Alkermes' Corporate Presentation to be Webcast at the Credit Suisse Healthcare ConferencePrinter Friendly Version
11/04/10Alkermes Reports Second Quarter Fiscal 2011 Financial ResultsPrinter Friendly Version
10/28/10Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2011Printer Friendly Version
10/25/10Alkermes Announces Positive Results from Phase 1 Study of ALKS 33 in Combination with Buprenorphine for Treatment of Cocaine AddictionPrinter Friendly Version
10/19/10Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™Printer Friendly Version
10/12/10Alkermes Announces FDA Approval of VIVITROL® for Prevention of Relapse to Opioid DependencePrinter Friendly Version
09/20/10Alkermes' Corporate Presentation to be Webcast at the UBS Global Life Sciences ConferencePrinter Friendly Version
09/16/10Alkermes Announces FDA Advisory Committee Recommends Approval of VIVITROL® for Opioid DependencePrinter Friendly Version
09/16/10Alkermes Stock Trading Halted TodayPrinter Friendly Version
09/14/10BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010Printer Friendly Version
09/14/10Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting for VIVITROL® for Opioid DependencePrinter Friendly Version
08/05/10Alkermes Reports First Quarter Fiscal 2011 Financial ResultsPrinter Friendly Version
07/29/10Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2011Printer Friendly Version
06/26/10BYDUREON™ Safety and Tolerability Pooled Summary Data Presented at ADA 2010Printer Friendly Version
06/17/10Alkermes Announces Notification of Tentative FDA Advisory Committee Meeting to Review VIVITROL® for Opioid DependencePrinter Friendly Version
06/15/10DURATION-4 Study Results: BYDUREON™ Efficacy and Tolerability Profile Extended to Monotherapy TreatmentPrinter Friendly Version
06/02/10Alkermes' Corporate Presentation to be Webcast at Two Upcoming ConferencesPrinter Friendly Version
05/25/10Alkermes Announces Priority Review by FDA for VIVITROL® for Opioid DependencePrinter Friendly Version
05/19/10Data on VIVITROL® to be Presented at Upcoming American Psychiatric Association Annual MeetingPrinter Friendly Version
05/13/10Alkermes Reports Financial Results for Fiscal 2010 and Provides Financial Expectations for Fiscal 2011Printer Friendly Version
05/06/10BYDUREON™ FDA Review Timeline Set with PDUFA Action Date of October 22, 2010Printer Friendly Version
05/05/10Alkermes to Host Conference Call to Discuss Fiscal Year 2010 Financial ResultsPrinter Friendly Version
04/26/10Alkermes to Provide Update on Advancing Product Portfolio and Proprietary Platforms at R&D DayPrinter Friendly Version
04/22/10Amylin, Lilly and Alkermes Submit Reply to FDA Complete Response Letter for BYDUREON™Printer Friendly Version
04/19/10Alkermes to Webcast R&D Day on Monday, April 26, 2010Printer Friendly Version
04/13/10Alkermes Submits Supplemental New Drug Application for VIVITROL® for the Treatment of Opioid DependencePrinter Friendly Version
03/17/10Alkermes Announces Initiation of Multidose Phase 1 Clinical Study of ALKS 37 for the Treatment of Opioid-Induced ConstipationPrinter Friendly Version
03/15/10Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly SubmissionPrinter Friendly Version
03/02/10Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 30th Annual Health Care ConferencePrinter Friendly Version
02/25/10Exenatide Once Weekly New Drug Application Review Extended by FDA Due to Weather-Related ClosurePrinter Friendly Version
02/16/10Alkermes Announces Positive Results for Phase 1 Study of New Drug Candidate for Treatment of Opioid-Induced ConstipationPrinter Friendly Version
02/04/10Alkermes Reports Third Quarter Fiscal 2010 Financial ResultsPrinter Friendly Version
02/04/10Alkermes Unveils Long-Acting Injectable Proprietary Platform for Treatment of Schizophrenia and Other CNS DisordersPrinter Friendly Version
02/01/10Alkermes' Corporate Presentation to be Webcast at the BIO CEO & Investor ConferencePrinter Friendly Version
01/28/10Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2010Printer Friendly Version
01/06/10Alkermes' Corporate Presentation to be Webcast at the 28th Annual JPMorgan Healthcare ConferencePrinter Friendly Version